Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

M. Hirschfield, Gideon; L. Shiffman, Mitchell; Gulamhusein, Aliya; V. Kowdley, Kris; M. Vierling, John; Levy, Cynthia; E. Kremer, Andreas; Zigmond, Ehud; Andreone, Pietro; C. Gordon, Stuart; L. Bowlus, Christopher; J. Lawitz, Eric; J. Aspinall, Richard; S. Pratt, Daniel; Raikhelson, Karina; S. Gonzalez-Huezo, Maria; A. Heneghan, Michael; Jeong, Sook-Hyang; L. Ladrón de Guevara, Alma; J. Mayo, Marlyn; N. Dalekos, George; P.H. Drenth, Joost; Janczewska, Ewa; A. Leggett, Barbara; Nevens, Frederik; Vargas, Victor; Zuckerman, Eli; Corpechot, Christophe; Fassio, Eduardo; Hinrichsen, Holger; Invernizzi, Pietro; J. Trivedi, Palak; Forman, Lisa; E.J. Jones, David; D. Ryder, Stephen; G. Swain, Mark; Steinberg, Alexandra; F. Boudes, Pol; Choi, Yun-Jung; A. McWherter, Charles; Study Group*, ENHANCE

doi:10.1097/hep.0000000000000395

Public

Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study

Published in Hepatology • Apr 6, 2023

Authors:

Gideon M. Hirschfield

Mitchell L. Shiffman

Aliya Gulamhusein

Abstract

Background and Aims: ENHANCE was a phase 3 study that evaluated efficacy and safety of seladelpar, a selective peroxisome proliferator-activated receptor-δ (PPAR) agonist, versus placebo in patients with primary biliary cholangitis with inadequate response or intolerance to ursodeoxycholic acid (UDC...

Discussions